Multiple gastric cancer tissue proteomic identification predicts CLU as a biomarker for anti-PD-1 immunotherapy
• Clusterin (CLU) is a new negative predictive biomarker for anti-PD-1 immunotherapy of gastric cancer (GC). • CLU is a pivotal regulator of both tumor-intrinsic proliferation and immune evasion in GC. • CLU abrogation in GC enhances the immune response, boosting T-cell killing ability activity and cytokine secretion.
Authors
- Piet A. Herdewijn (ORCID: https://orcid.org/0000-0003-3589-8503)
- Ning-Jie Guo
- Xing‐Jie Dai (ORCID: https://orcid.org/0000-0001-7531-044X)
- Guo‐Liang Lu (ORCID: https://orcid.org/0000-0002-2094-0820)
- Fengyu Qi
- Yong Zhang (ORCID: https://orcid.org/0000-0003-2179-3698)
- Congcong Ma (ORCID: https://orcid.org/0000-0002-5182-7556)
- Xiaoying Zhao (ORCID: https://orcid.org/0000-0003-3622-405X)
- Jingru Pang
- Hong-Min Liu
- Hao-Yi Zhu
- Jian-Gang Sun
- Feng-Wu Liu
- Ning Wang
- MAA Mamun
- Ying Li
- Bo Wang
- Yan Li
Institutions
- Ministry of Education (NZ)
- University of Auckland (NZ)
- PLA Information Engineering University (CN)
- Shanghai Jiao Tong University (CN)
- Rega Institute for Medical Research (BE)
- Zhengzhou University (CN)
- Auckland University of Technology (NZ)
- Cancer Society of New Zealand (NZ)
- Maurice Wilkins Centre (NZ)
- First Affiliated Hospital of Zhengzhou University (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Journal of Pharmaceutical Analysis
- Published
- 2026-04-01
- DOI
- https://doi.org/10.1016/j.jpha.2026.101615
- Primary Topic
- Clusterin in disease pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.00